Dirk Thye‚ M.D.
President, Cerexa, Inc.

Dirk Thye is the President of Cerexa. Dr. Thye has extensive experience in anti–infective research and clinical development in both domestic and international markets. Prior to joining Cerexa‚ Dr. Thye was a founder and Senior Vice President of Clinical Development at Peninsula Pharmaceuticals where he was responsible for the clinical development of Peninsula’s anti–infective portfolio. Prior to founding Peninsula‚ Dr. Thye led the clinical development program at Vicuron Pharmaceuticals for anidulafungin‚ a systemic antifungal compound which has been approved for commercial use and was subsequently acquired by Pfizer in 2005. Dr. Thye is board certified in Internal Medicine and graduated with honors from UCLA School of Medicine. He completed his post–graduate training in Internal Medicine at the Stanford University Medical Center. Dr. Thye also holds a B.A. in Molecular Biology from the University of California at Berkeley.

Ian A. Critchley, Ph.D.
Vice President, Clinical Microbiology

Ian Critchley is the Vice President of Clinical Microbiology at Cerexa. Dr. Critchley joined Cerexa in June 2008 and brings more than 20 years of experience in antibacterial drug discovery and development. Prior to joining Cerexa, Dr. Critchley was Executive Director of Microbiology at Replidyne, where he led a team responsible for all pre-clinical and clinical microbiology studies on antibacterial agents in the development pipeline. Dr. Critchley came to Replidyne from Focus Technologies (now Eurofins Medinet) where he was Director of Laboratory Services and established the microbiology laboratory that provides contract research services to evaluate new agents in IND and NDA-enabling studies and monitors resistance in global surveillance studies. Prior to joining Focus Technologies, Dr. Critchley was a Senior Investigator and Group Leader in Microbiology Research at SmithKline Beecham Pharmaceuticals where he led discovery research groups in both the U.K. and Philadelphia. Dr. Critchley holds a Ph.D. in Microbiology obtained from the University of Glasgow, Scotland, U.K. and a B.Sc. (Hons) in Microbiology obtained from University College Cardiff, Wales, U.K. Dr. Critchley is a member of the American Society for Microbiology, the U.K. Society for General Microbiology and the British Society for Antimicrobial Chemotherapy.

David Friedland, M.D.
Vice President, Clinical Sciences

David Friedland is the Vice President of Clinical Sciences at Cerexa. Dr. Friedland joined Cerexa in June 2008 and has extensive experience in the field of infectious diseases, encompassing both academia and the pharmaceutical industry. Prior to joining Cerexa, Dr. Friedland was Senior Director of Clinical Research at Theravance from 2005, where he was responsible for the hospital-acquired pneumonia program and a major contributor to the NDA for telavancin, a gram-positive antibacterial agent. Dr. Friedland came to Theravance from Migenix, a biopharmaceutical company in Vancouver, BC, where he developed antibacterial and antiviral agents. Dr. Friedland served in various positions over an eight-year period, most recently as Vice President, Clinical and Medical Affairs. Dr. Friedland obtained his M.D. and Master of Medicine (Microbiology) degree from the University of the Witwatersrand, Johannesburg, South Africa. He also holds an M.B.A. from Queens University, ON, Canada and is a Fellow of the Infectious Diseases Society of America.

Jon Lee
Vice President, Clinical Operations

Jon Lee, Vice President of Clinical Operations, joined Cerexa in June 2006. Mr. Lee served in positions of increasing responsibilities at Nektar Therapeutics/inhale from 1999 until joining Cerexa. Prior to Nektar, he held various positions within Clinical Operations at Gilead Sciences and Genentech Inc. Mr. Lee has developed and managed departments and interdisciplinary project teams in each discipline of drug development in such therapeutic areas as infectious disease, oncology, neurology, and pulmonology. Mr. Lee graduated from the University of Illinois with a B.S. in Chemistry.

Trisha Dobson, M.B.A., P.M.P.
Executive Director, Project Management

Trisha Dobson is the Executive Director of Project Management at Cerexa. Ms. Dobson was part of the team that founded Cerexa and heads the Project Management function. Ms. Dobson has worked in many stages of development throughout her career and currently leads the product team for a key antibiotic product. Prior to Cerexa, Ms. Dobson held positions in Project Management at Peninsula Pharmaceuticals, which was acquired by Johnson & Johnson. Prior to working at Peninsula Pharmaceuticals, Ms. Dobson developed and directed the Project Management department at Cerus, instituting a number of key business and strategic management tools. She has been in the industry for more than 15 years, focusing most recently on Project Management. She has worked in both the pharmaceutical and diagnostic environments, and has held key roles on a number of international projects. Ms. Dobson received a B.S. from Case Western University and holds an M.B.A. from St. Mary’s University. Ms. Dobson is a certified P.M.P., Project Management Professional.

Dan Puckett, M.B.A.
Executive Director, Operations

Dan Puckett is the Executive Director of Operations at Cerexa. Mr. Puckett joined Cerexa in April 2009 and brings extensive experience in corporate finance, strategic planning, and operations management. Prior to joining Cerexa‚ Mr. Puckett was Vice President/General Manager, Global Sales Operations at Affymetrix, a leading manufacturer of microarray technologies used for analyzing complex genetic information. In this capacity, Mr. Puckett had full responsibility for all sales and commercial support within the $410M business. Prior to Affymetrix, Mr. Puckett served as Executive Director of Finance at AOL, managing financial and operational initiatives for the Western U.S. Interactive Media Sales Business Unit, and as Director of Finance at Netscape, where he established and managed financial reporting, processes, and procedures to optimize performance and drive revenue growth. Mr. Puckett started his career at BHP Billiton, the world’s largest diversified resources company, where he held finance roles of increasing responsibility, including key assignments in Canada and Australia. Mr. Puckett holds an M.B.A. from the University of San Francisco and a B.A. in Accounting from Washington State University.